Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Crystal RG, et al. Among authors: kessler pd. Hum Gene Ther. 2002 Jan 1;13(1):65-100. doi: 10.1089/10430340152712647. Hum Gene Ther. 2002. PMID: 11779413 Clinical Trial.
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Harvey BG, et al. Among authors: kessler pd. Hum Gene Ther. 2002 Jan 1;13(1):15-63. doi: 10.1089/10430340152712638. Hum Gene Ther. 2002. PMID: 11779412 Clinical Trial.
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Stewart DJ, et al. Among authors: kessler pd. Gene Ther. 2006 Nov;13(21):1503-11. doi: 10.1038/sj.gt.3302802. Epub 2006 Jun 22. Gene Ther. 2006. PMID: 16791287 Clinical Trial.
Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Rajagopalan S, et al. Among authors: kessler pd. Circulation. 2003 Oct 21;108(16):1933-8. doi: 10.1161/01.CIR.0000093398.16124.29. Epub 2003 Sep 22. Circulation. 2003. PMID: 14504183 Clinical Trial.
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. Mundt AJ, et al. Among authors: kessler pd. Clin Cancer Res. 2004 Sep 1;10(17):5747-53. doi: 10.1158/1078-0432.CCR-04-0296. Clin Cancer Res. 2004. PMID: 15355902 Clinical Trial.
A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.
Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A, Macko J, Kessler PD, Rasmussen HS, Epstein SE, Kornowski R. Fuchs S, et al. Among authors: kessler pd. Catheter Cardiovasc Interv. 2006 Sep;68(3):372-8. doi: 10.1002/ccd.20859. Catheter Cardiovasc Interv. 2006. PMID: 16892433 Clinical Trial.
147 results